Aurelia Bioscience is a UK-based Contract Research Organisation (CRO) specialising in bioassay development, pharmacological profiling and high throughput screening. They use cutting edge assay technologies to effectively and reliably move novel compounds or biologics through the multiple stages of early drug discovery.
Examples of expertise:
- Phenotypic screening
- 3D cell biology of single or multiple cell populations
- Cell-based screening
- Innovative technologies: label free, WES Western blotting, High Content
- New approaches to Kinase compound profiling
Scientists at Aurelia Bioscience have decades of experience in pre-clinical discovery, designing and developing low, medium and high throughput assays for hits-to-lead, lead identification and lead optimisation. In their eight years in business, they have delivered a wide range of early stage drug discovery projects in a timely, efficient and cost-effective manner.